Status:
COMPLETED
OSCA - Olaparib Standard of CAre Study
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
RTI Health Solutions
A+A Healthcare Marketing Research
Conditions:
Platinum-sensitive Recurrent Serous Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This study will be carried out as a retrospective, non-interventional observational review of medical records for patients in multiple countries with platinum-sensitive recurrent serous ovarian cancer...
Eligibility Criteria
Inclusion
- First determined to have platinum-sensitive recurrent serous ovarian cancer between January 1, 2009, and December 31, 2013 (study entry period), as defined by no evidence of disease progression for at least 6 months after completion of a first-line platinum-based chemotherapy regimen; the first date of platinum-sensitive recurrence between January 1, 2009 and December 31, 2013 will define the study index date.
- At least 18 years of age on the index date.
- Fully documented medical history related to the patient's ovarian cancer treatment beginning with initial diagnosis of serous ovarian cancer.
- Patients can be either alive or deceased at the time of medical record abstraction.
Exclusion
- 1\. Ever taken an investigational product as part of an interventional clinical trial for ovarian cancer.
Key Trial Info
Start Date :
October 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2016
Estimated Enrollment :
2123 Patients enrolled
Trial Details
Trial ID
NCT02262273
Start Date
October 1 2014
End Date
April 1 2016
Last Update
March 1 2017
Active Locations (199)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Ballarat, Australia
2
Research Site
Birtinya, Australia
3
Research Site
Campbelltown, Australia
4
Research Site
East Melbourne, Australia